Next Article in Journal
Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19
Next Article in Special Issue
The Evidence for Effective Inhibition of INa Produced by Mirogabalin ((1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo [3.2.0] hept-3-ene-6-acetic acid), a Known Blocker of CaV Channels
Previous Article in Journal
Polymodal Control of TMEM16x Channels and Scramblases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 3
10.3390/ijms23031582
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice

by
Donghui Bai
1,
Tianxiao Sun
1,
Fang Lu
1,
Yancheng Shen
1,
Yan Zhang
1,
Bo Zhang
1,
Guangli Yu
1,2,3,
Haihua Li
1,* and
Jiejie Hao
1,3,*
1
Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
2
Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
3
Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology (Qingdao), Qingdao 266237, China
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(3), 1582; https://doi.org/10.3390/ijms23031582
Submission received: 23 December 2021 / Revised: 17 January 2022 / Accepted: 24 January 2022 / Published: 29 January 2022
(This article belongs to the Special Issue Chronic Inflammation and Related Diseases: From Mechanisms to Therapies)
Browse Figures
Versions Notes

Abstract

:
To investigate the effect of eupatilin in asthma treatment, we evaluated its therapeutic effect and related signal transduction in OVA-induced asthmatic mice and LPS-stimulated RAW264.7 cells. The BALF was tested for changes in lung inflammatory cells. Th2 cytokines in the BALF and OVA-IgE in the serum were measured by ELISA. H&E and PAS staining were used to evaluate histopathological changes in mouse lungs. The key proteins NF-κB, MAPK, and Nrf2 in lung tissues were quantitatively analyzed by Western blotting. Finally, we evaluated the effect of eupatilin on cytokines and related protein expression in LPS-stimulated RAW 264.7 cells in vitro. In OVA-induced asthmatic mice, eupatilin reduced the numbers of inflammatory cells, especially neutrophils and eosinophils. Eupatilin also decreased the levels of IL-5, IL-13 in the BALF and OVA-IgE in the serum. Furthermore, eupatilin inhibited the activation of NF-κB and MAPK pathways and increased the expression of Nrf2 in OVA-induced asthmatic mice. In vitro, eupatilin significantly reduced LPS-stimulated NO, IL-6, and ROS production. Additionally, the NF-κB, MAPK, and Nrf2 protein expression in LPS-stimulated RAW264.7 cells was consistent with that in OVA-induced asthmatic lung tissues. In summary, eupatilin attenuated OVA-induced asthma by regulating NF-κB, MAPK, and Nrf2 signaling pathways. These results suggest the utility of eupatilin as an anti-inflammatory drug for asthma treatment.
Keywords:
asthma; eupatilin; NF-κB; MAPK; Nrf2

1. Introduction

Asthma is a common chronic respiratory inflammatory disease [1]. It is characterized by airway hyperresponsiveness, allergen-specific IgE secretion, mucus hypersecretion, and airway inflammation [2,3]. In recent years, the incidence of asthma has increased due to increases in indoor dust, pollen, toxic particles, environmental pollutants, and other allergens [4]. It is estimated that 241 million people worldwide suffer from asthma, with 1000 people dying every day [5]. At present, asthma cannot be cured but can only be controlled by medicine, which brings serious physical and psychological damage to patients.
Previous studies have suggested that the imbalance between Th1 and Th2 cells is the major cause of asthma [6]. Th2 cells play a vital role in asthmatic progression [7,8]. Activated Th2 cells oversecrete the cytokines IL-4, IL-5, and IL-13, promoting airway inflammation and remodeling [9,10]. Among these cytokines, IL-5 is central to the asthmatic phenotype, as it can affect the growth, survival, differentiation, and recruitment of eosinophils [11,12]. IL-13 can induce eosinophils to infiltrate lung tissue and directly cause airway inflammation and airway hyperresponsiveness [13,14]. Thus, antagonizing the action of Th2 cytokines represents one of the major therapeutic strategies in the treatment of asthma. In addition, the causes of many problems related to asthma remain unclear, so investigations into the pathogenesis of asthma and identification of new therapeutic targets are urgently needed.
In addition to related cytokines, a host of signaling pathways are known to be involved in the pathophysiology process of asthma, including NF-κB, MAPK, and Nrf2 signaling pathways. NF-κB is a transcription factor that can regulate the production of many cytokines and play a central role in modulating inflammatory and immune responses [15,16]. NF-κB is continuously activated in allergic asthma, and NF-κB inhibition can significantly alleviate ovalbumin (OVA)-induced asthma [17]. Furthermore, it has been confirmed that activation of the mitogen-activated protein kinase (MAPK) pathway is closely associated with airway inflammation [15]. The MAPK family is composed of p38 MAPK, Erk, and JNK. It has been clearly reported that the levels of phosphorylated p38 MAPK, Erk, and JNK are significantly elevated in the airways of patients with allergic asthma and that this increased expression correlates with the severity of asthma [18]. In addition, nuclear factor-erythroid 2-related factor 2 (Nrf2), which is associated with transcriptional activation of the antioxidant response element (ARE) gene, is beneficial in asthma, acting through anti-inflammatory mechanisms [19]. In summary, NF-κB, MAPK, and Nrf2 pathways have become key targets in the treatment of asthma. Therefore, inhibiting NF-κB and MAPK family members while enhancing Nrf2 pathway activity may be an effective approach for preventing or treating asthma.
It has been reported that many traditional Chinese herbs are effective in reducing asthma symptoms in both humans and animals [20]. Eupatilin [2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one] (Figure 1), a pharmacologically active flavone extracted from Artemisia argyi, has a variety of pharmacological activities, including anti-inflammatory, anticancer, antioxidant, antiallergic, cardioprotective, and neuroprotective activities [21,22]. Eupatilin suppresses inflammatory responses by inhibiting the NF-κB signaling pathway and reducing the lipopolysaccharide (LPS)-stimulated production of inflammatory cytokines [23]. Eupatilin has also been found to inhibit TNF-α-induced eosinophil migration [24]. In addition, it has been shown that eupatilin can inhibit allergic inflammatory reactions both in vitro and in vivo, suggesting that eupatilin may be used to treat inflammatory diseases associated with allergic disorders [25,26]. Currently, there are very few studies on eupatilin in lung diseases in mice, and the only report is that eupatilin could attenuate acute lung injury in mice by inhibiting inflammation and oxidative stress [27]. However, the therapeutic activity of eupatilin against asthma in vivo and its associated mechanism have not been studied. In the present study, we first investigated the anti-asthmatic activity and possible mechanism of eupatilin in OVA-induced asthmatic mice and verified it in LPS-stimulated RAW264.7 cells.

2. Results

2.1. Effect of Eupatilin on Inflammatory Cells in the Bronchoalveolar Lavage Fluid (BALF)

In this study, the effect of eupatilin on the profile of inflammatory cells in the BALF was detected. As shown in Figure 2, compared with the control group, the OVA group showed significantly increased numbers of total inflammatory cells, neutrophils, lymphocytes, monocytes, and eosinophils in the BALF. Eupatilin administration could reduce the number of inflammatory cells in the BALF, especially neutrophils and eosinophils, to varying degrees, indicating that eupatilin could alleviate inflammatory cell infiltration in the lungs of asthmatic mice.

2.2. Eupatilin Reduces OVA-Induced Th2 Cytokine Levels in the BALF and OVA-IgE Levels in the Serum

In asthma, inflammatory responses are closely associated with the activation of Th2 cells [28]. Th2 cytokines can activate eosinophils and induce B cells to produce IgE [29]. Compared with control treatment, OVA sensitization and challenge significantly increased the production of IL-5, IL-13, and OVA-IgE (Figure 3). However, eupatilin administration inhibited the increase of these cytokines in a dose-dependent manner, and it was also significantly more effective than dexamethasone at a dose of 30 mg/kg.

2.3. Effect of Eupatilin on Lung Histological Changes in Asthmatic Mice

Inflammatory cell infiltration and mucus secretion are the key features of allergic asthma. Hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) staining analyses were used to detect histological changes in lung tissues. As shown in Figure 4a, lung tissues from the OVA group exhibited significant inflammatory cell infiltration. Additionally, PAS staining showed that the mice in the OVA group overproduced mucus (Figure 4b). However, eupatilin treatment could significantly improve the inflammatory cell infiltration induced by OVA and remarkably inhibit mucus hypersecretion, which were comparable with the effect of dexamethasone.

2.4. Effect of Eupatilin on NF-κB, MAPK and Nrf2 Signaling Pathways in Asthmatic Mice

NF-κB and MAPK are key targets associated with inflammation and play an important role in asthma inflammation. To explore the effect of eupatilin on NF-κB and MAPK signaling pathways, the protein levels of p-NF-κB p65, p-p38 MAPK, p-Erk, and p-JNK were detected by Western blotting (Figure 5a). Compared with OVA induction alone, eupatilin treatment significantly inhibited the OVA-induced phosphorylation of NF-κB (Figure 5b). Furthermore, we observed that the levels of phosphorylated MAPK family members (p38 MAPK, Erk, and JNK) were significantly enhanced in the OVA group, whereas eupatilin treatment significantly inhibited the activation of p38 MAPK, Erk, and JNK (Figure 5c–e).
Inflammation itself leads to oxidative stress in the airways and lungs, further exacerbating the inflammatory response [30]. Therefore, the protein expression levels of Nrf2 in lung tissues were evaluated. The results show that OVA administration significantly inhibited Nrf2 expression, while Nrf2 expression levels were significantly increased after eupatilin administration, and the effect was comparable with that of dexamethasone (Figure 5f). These results suggest that eupatilin could alleviate the inflammatory reactions in asthma by affecting NF-κB, MAPK, and Nrf2 signaling pathways.

2.5. Effect of Eupatilin on Inflammatory Cytokines in RAW264.7 Cells

Previous studies have revealed that alveolar macrophages may play a central role in promoting airway inflammation [31]. After treatment with different concentrations of eupatilin, the observed cell viability was not significantly different from that of the control group, indicating that eupatilin had no significant cytotoxicity up to a dose of 200 μmol/L (Figure 6a). Compared with the LPS group, eupatilin significantly reduced the release of NO and IL-6, with eupatilin acting in a dose-dependent manner (Figure 6b,c). Furthermore, LPS significantly induced ROS production in RAW264.7 cells, while eupatilin significantly inhibited ROS production (Figure 6d). These results suggest that eupatilin had anti-inflammatory activity in LPS-stimulated RAW264.7 cells.

2.6. Effect of Eupatilin on NF-κB, MAPK, and Nrf2 Signaling Pathways in RAW264.7 Cells

To further verify the therapeutic target of eupatilin in asthma, we detected the protein expression of p-NF-κB p65, p-MAPK, and Nrf2 in LPS-stimulated RAW264.7 cells (Figure 7a). The levels of phosphorylated NF-κB p65, p38 MAPK, Erk, and JNK in the LPS group were significantly increased, while eupatilin significantly inhibited the phosphorylation of these proteins (Figure 7b–e). In addition, compared with the LPS group, the eupatilin group showed significantly elevated expression of Nrf2 (Figure 7f). The protein expression trends in LPS-stimulated RAW264.7 cells were consistent with those in mouse lung tissues, further indicating that eupatilin exerted its anti-inflammatory effects in asthma through effects on NF-κB, MAPK, and Nrf2 signaling pathways.

3. Discussion

Asthma is a recurrent chronic airway inflammatory disease involving multiple inflammatory cells and mediators [32,33]. Glucocorticoids are considered to be the best choice to treat asthma. However, they have limited efficacy and can cause various adverse reactions. Therefore, there is an urgent need to find a new, safer, and more effective drug to treat asthma [34,35]. Pharmacological and phytochemical studies have identified many potential anti-inflammatory ingredients, especially options derived from traditional Chinese medicine, so traditional Chinese herbal medicine is becoming an important source of active drugs [36]. Eupatilin has good anti-inflammatory activity, but its therapeutic activity in asthma has not been explored. Our results confirm that eupatilin attenuated OVA-induced asthma by inhibiting NF-κB and MAPK and activating Nrf2 signaling pathways.
The inflammatory responses in asthma involve the excessive production of IgE by B cells, release of inflammatory cytokines, and infiltration of inflammatory cells [37]. A variety of inflammatory cells are involved in airway inflammation, such as macrophages, eosinophils, lymphocytes, and neutrophils [38,39]. Among them, eosinophils are the main contributors to allergic inflammation and are involved in the induction of airway hyperresponsiveness and remodeling in asthma [40,41]. In this study, our results show that eupatilin could reduce the number of inflammatory cells in the BALF, especially neutrophils and eosinophils. Th2 cells play a key role in the pathogenesis of allergic asthma inflammation [42,43]. Th2 cytokines, including IL-5 and IL-13, are involved in eosinophil accumulation, mucus hypersecretion, and allergen-specific IgE secretion [44]. In this study, OVA sensitization and challenge could significantly increase the production of IL-5, IL-13, and OVA-IgE. Eupatilin administration inhibited the increase of IL-5, IL-13, and OVA-IgE in a dose-dependent manner, and the effects were better than dexamethasone. In addition, eupatilin treatment could significantly improve inflammatory cell infiltration induced by OVA and could remarkably inhibit mucus hypersecretion, which were comparable with the effect of dexamethasone. These results suggest that eupatilin could play an anti-asthmatic role by reducing inflammatory cell infiltration.
Next, we further explored the molecular mechanisms of eupatilin on OVA-induced asthma. Many studies have shown that NF-κB, MAPK, and Nrf2 are important targets in the treatment of asthma. NF-κB, one of the most studied transcription factors, plays an important role in the mechanisms of various acute and chronic inflammatory conditions, including asthma [45,46,47]. In general, NF-κB binds to IκB in the cytoplasm in an inactive state. When IκB is phosphorylated by the IκB kinase complex (IKK), NF-κB is released and transported to the nucleus, triggering multiple intracellular inflammatory signaling pathways [48,49]. The activation of NF-κB promotes the expression of inflammatory factors, such as NO, COX-2, and IL-6, and the secretion of Th2 cytokines (IL-4, IL-5, and IL-13) in allergic airway inflammation [50]. MAPKs (p38 MAPK, Erk, and JNK) can regulate cellular responses to external stimuli and various cellular activities such as apoptosis, differentiation, inflammation, and gene expression [51,52]. Inhibitors targeting MAPKs have been developed to treat a variety of inflammatory diseases [53]. Nrf2 is one of the most important antioxidative stress proteins. When stimulated, Nrf2 is activated and binds to the ARE, thereby activating the transcription of antioxidant genes [54]. In our results, eupatilin significantly inhibited the phosphorylation of NF-κB, p38 MAPK, Erk, and JNK and increased the expression of Nrf2 in OVA-induced mice. These findings suggest that eupatilin attenuated asthma through NF-κB, MAPK, and Nrf2 signaling pathways.
Macrophages also play an important role in asthma, and the inflammatory factors produced by macrophages, such as IL-6, NO, and ROS, are also important markers of asthma [55,56,57]. NF-κB, MAPK, and Nrf2, as inflammatory signaling pathways, were activated after LPS stimulation of macrophages [58]. Although the mechanism of macrophage stimulation by LPS is very different from the sensitization process observed in asthma, macrophages are also important targets for asthma treatment. In this study, we used LPS stimulation to assess the anti-inflammatory activity and mechanisms of eupatilin. We found that eupatilin reduced NO, IL-6, and ROS levels in RAW264.7 cells and had a relatively good anti-inflammatory effect. Furthermore, eupatilin significantly inhibited the phosphorylation of NF-κB, p38 MAPK, Erk, and JNK and increased the expression of Nrf2 in LPS-stimulated RAW264.7 cells. The protein expression trends in LPS-stimulated RAW264.7 cells were consistent with those in animal lung tissues, further indicating that eupatilin exerted an anti-inflammatory effect in asthma through NF-κB, MAPK, and Nrf2 signaling pathways.
In summary, eupatilin attenuated OVA-induced asthma by regulating NF-κB, MAPK, and Nrf2 signaling pathways. Eupatilin may be a promising therapeutic agent for the treatment of asthma.

4. Materials and Methods

4.1. Drugs and Reagents

Eupatilin (Eup, purity ≥ 98%) was purchased from Nanjing Spring & Autumn Biological Co., Ltd. (Nanjing, China). Dexamethasone (Dex) was purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). Aluminum hydroxide [Al(OH)3] was purchased from Thermo Fisher Scientific (Waltham, MA, USA), and OVA was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Mouse IL-6, IL-5, IL-13, and OVA-IgE enzyme-linked immunosorbent assay (ELISA) kits were purchased from Shanghai FANKEW Industrial Co., Ltd. (Shanghai, China). BCA protein detection kit and NO and ROS assay kits were purchased from Beyotime Biotechnology (Shanghai, China). Antibodies against p-NF-κB p65 (3033T), NF-κB p65(8242T), p-p38 MAPK (4511T), p38 MAPK (8690T), p-Erk (4370T), Erk (4695T), p-JNK (4668T), Nrf2 (12721T), and GAPDH (5174T) were obtained from Cell Signaling Technology (CST; Beverly, MA, USA). An antibody against JNK (sc-7345) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Fetal bovine serum (FBS) and DMEM medium were purchased from Gibco (Grand Island, NY, USA).

4.2. Animals

Female BALB/c mice (6–8 weeks) were obtained from Jinan Pengyue Laboratory Animal Co., Ltd. (Jinan, China). The mice were given plenty of food and water, housed at 25 °C under a 12 h light/dark cycle. Before experimentation, the mice were acclimatized to feeding in the experimental environment for 1 week. All animal experiments were carried out in accordance with the guidelines of the Animal Experiments Ethics Committee of Ocean University of China (OUC-SMP-2021-02-02).

4.3. Sensitization and Treatment Protocols

A total of 35 mice were randomly divided into 5 groups with 7 mice in each group: the control group, OVA group, OVA + Dex (1 mg/kg) group, OVA + Eup 15 group, and OVA + Eup 30 group. Dex was used as the positive control drug. The OVA-induced asthmatic model was established as described in a previous study [59]. Briefly, each mouse was sensitized by intraperitoneal injection of 20 μg OVA and 2 mg aluminum hydroxide in 200 μL PBS on days 0, 7, and 14. On days 21, 22, and 23, the OVA-challenged mice were exposed to ultrasonic atomization of 5% OVA for 30 min each day. The mice in the control group were sensitized and challenged with an equal amount of PBS instead of OVA. From day 17 to day 23, mice were treated with eupatilin (15 mg/kg, 30 mg/kg), Dex (1 mg/kg) or an equal amount of 0.9% NaCl solution by intraperitoneal injection. The mice were sacrificed 24 h after the last challenge.

4.4. BALF Collection and Leukocyte Counts

Twenty-four hours after the last challenge, the trachea was intubated, and the lungs were washed with 0.7 mL PBS twice to collect the BALF. The BALF was centrifuged at 1500× g rpm for 10 min, and the supernatants were collected and stored at –80 °C for cytokine detection. The cell precipitates in the BALF were suspended in 100 µL PBS, and the total numbers of white blood cells, neutrophils, lymphocytes, monocytes, and eosinophils in the BALF were determined with ProCyte Dx® Hematology Analyzer (IDEXX Laboratories Inc., Westbrook, ME, USA).

4.5. Determination of IL-5, IL-13 and OVA-IgE Levels

The levels of IL-5 and IL-13 in the BALF and OVA-specific IgE in the serum were determined by ELISA, as described in the corresponding kit instructions.

4.6. H&E and PAS Staining

Lung tissues were fixed in 4% paraformaldehyde. Then, the lungs were dehydrated, embedded in paraffin, and sectioned. The sections were stained with H&E or PAS. Finally, the histopathologic changes and mucus content of the lung tissues were examined under a light microscope. Three random fields of each sample were selected at random and photographed under 200× magnification.

4.7. Cell Culture and Treatment

The RAW264.7 cell line was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% inactivated fetal bovine serum (FBS) in an atmosphere of 5% CO2 at 37 °C.
First, RAW264.7 cells (2 × 104 cells/well) were grown in 96-well plates for 12 h. Then, the cells were treated with 1 μg/mL LPS for 24 h to establish a model of inflammation.

4.8. MTT Assay

After RAW264.7 cells were treated with different concentrations (10, 25, 50, 100, 200 μmol/L) of eupatilin for 24 h, the effect of eupatilin on cell viability was monitored with the MTT assay. An MTT solution (5 mg/mL in PBS buffer, 20 μL) was added and incubated with the cells for 4 h. Then, the culture medium was replaced with 150 μL DMSO to dissolve the formed violet crystals. Finally, the absorbance was measured at 490 nm [60].

4.9. Measurement of NO

NO content in the cell supernatant was measured using Griess reagent [61]. First, RAW264.7 cells (2 × 104/well) were seeded in 96-well plates for 12 h. Second, RAW264.7 cells were treated with different concentrations (10, 25, 50, 100 μmol/L) of eupatilin and 1 μg/mL LPS for 24 h. After treatment, 50 μL supernatant from each well was mixed with 50 μL Griess Reagent I and 50 μL Griess Reagent II and then incubated for 10 min at room temperature. The optical density was determined at 540 nm.

4.10. Measurement of ROS

Intracellular ROS levels were measured using 2′,7′-dichlorofluorescein-diacetate (DCFH-DA) [62]. DCFH-DA is readily oxidized by intracellular ROS to fluorescent DCF. RAW264.7 cells (5 × 105/well) were cultured in 6-well plates for 12 h. Then, cells were treated with different concentrations (10, 25, 50, 100 μmol/L) of eupatilin and 1 μg/mL LPS for 24 h. Following LPS and eupatilin treatment, RAW264.7 cells were incubated with 10 µmol/L DCFH-DA for 20 min at 37 °C and then washed three times with PBS. Finally, the fluorescence was measured under a fluorescence microscope at an excitation wavelength of 488 nm and an emission wavelength of 525 (Nikon Corporation, Tokyo, Japan).

4.11. Measurement of IL-6

RAW264.7 cells (2 × 104/well) were cultured in 96-well plates for 12 h. Then, cells were treated with different concentrations (10, 25, 50, 100 μmol/L) of eupatilin and 1 μg/mL LPS for 24 h. After treatment, absorbing cell supernatants, IL-6 levels in cell supernatants were determined using ELISA kits according to the manufacturer’s instructions.

4.12. Western Blot Analysis

RAW264.7 cells were seeded in six-well plates at a density of 5 × 105 cells/well. After 24 h of treatment with LPS and eupatilin, the RAW264.7 cells were washed with cold PBS and then lysed in 200 µL RIPA buffer containing phosphatase inhibitors and protease inhibitors for 20 min. An amount of 100 mg lung tissue was added with 1 mL RIPA buffer containing phosphatase inhibitors and protease inhibitors, homogenized, and placed on ice for 20 min.
The lysate was centrifuged at 12,000× g rpm and 4 °C for 10 min, and the supernatant was stored at –80 °C. The protein concentration was determined with a BCA protein detection kit. Thirty micrograms of protein was added to each well, separated by 10% SDS–PAGE, and transferred to PVDF membranes. The membranes were blocked with 5% skim milk for 90 min and then incubated with a primary antibody at 4 °C overnight. Then, the membranes were washed with TBST three times and incubated with an appropriate secondary antibody. Then, the bands were visualized using an enhanced chemiluminescence (ECL) kit (Pierce Biotechnology, Rockford, IL, USA). Finally, ImageJ software (NIH, Bethesda, MD, USA) was used for gray integration analysis.

4.13. Statistical Analysis

Data are expressed as the mean ± SEM. GraphPad Prism 9.0 software (San Diego, CA, USA) was used for statistical analysis, and one-way ANOVA followed by multiple comparison tests was performed. Statistical significance was accepted at p < 0.05.

Author Contributions

D.B. conducted the research and wrote the paper. T.S., F.L. and G.Y. performed the experiments and analyzed the data. Y.S., Y.Z. and B.Z. helped with animal feeding. H.L. and J.H. designed and directed the project. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81973231, 81402982, and 81991522), Qingdao National Laboratory for Marine Science and Technology (2016ASKJ08-2), and Taishan Scholar Project Special Funds (TSPD20210304).

Institutional Review Board Statement

The animal experimental protocol was performed following the ethical standards of ARRIVE guidelines, and efforts were made to minimize animal suffering. Animal experiments were approved by the Ethics and Animal Welfare Committee of the Ocean University of China (OUC-SMP-2021-02-02).

Conflicts of Interest

The authors declare that they have no conflict of interest.

Abbreviations

NF-κB nuclear factor kappa B
MAPKsmitogen-activated protein kinases
JNKc-Jun N-terminal kinase
Nrf2nuclear factor-erythroid 2-related factor 2
OVAovalbumin
Dexdexamethasone
BALFbronchoalveolar lavage fluid
LPSlipopolysaccharide
FBSfetal bovine serum
MTT3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
ROSreactive oxygen species

References

  1. Luo, X.Q.; Zhong, J.W.; Qiu, S.Y.; Zhi, M.; Yang, L.Q.; Zhou, Y.L.; Zhou, F.X.; Yang, P.C.; Liu, D.B.; Mo, L.H. A20-OVA nanoparticles inhibit allergic asthma in a murine model. Inflammation 2020, 43, 953–961. [Google Scholar] [CrossRef] [PubMed]
  2. Tian, D.; Yang, L.; Wang, S.; Zhu, Y.; Shi, W.; Zhang, C.; Jin, H.; Tian, Y.; Xu, H.; Sun, G.; et al. Double negative T cells mediate Lag3-dependent antigen-specific protection in allergic asthma. Nat. Commun. 2019, 10, 4246. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, J.; Zhou, Y.; Gu, H.; Zhang, J.; Tang, H.; Rong, Q.; Gu, L.; Pan, J.; Zhao, D.; Liu, F. LncRNA-AK149641 associated with airway inflammation in an OVA-induced asthma mouse model. J. Bioenerg. Biomembr. 2020, 52, 355–365. [Google Scholar] [CrossRef] [PubMed]
  4. Ko, J.W.; Kwon, H.J.; Seo, C.S.; Choi, S.J.; Shin, N.R.; Kim, S.H.; Kim, Y.H.; Kim, J.C.; Kim, M.S.; Shin, I.S. 4-Hydroxycinnamic acid suppresses airway inflammation and mucus hypersecretion in allergic asthma induced by ovalbumin challenge. Phytother. Res. 2020, 34, 624–633. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, C.; Tang, J.; Qian, B.; Zeng, Z.; Gao, Y.; Song, J.L. Rubusoside alleviates the ovalbumin-induced mice allergic asthma by modulating the NF-κB activation. J. Food Biochem. 2020, 44, e13187. [Google Scholar] [CrossRef] [PubMed]
  6. Ji, N.F.; Xie, Y.C.; Zhang, M.S.; Zhao, X.; Cheng, H.; Wang, H.; Yin, K.S.; Huang, M. Ligustrazine corrects Th1/Th2 and Treg/Th17 imbalance in a mouse asthma model. Int. Immunopharmacol. 2014, 21, 76–81. [Google Scholar] [CrossRef]
  7. Franova, S.; Joskova, M.; Sadlonova, V.; Pavelcikova, D.; Mesarosova, L.; Novakova, E.; Sutovska, M. Experimental model of allergic asthma. Adv. Exp. Med. Biol. 2013, 756, 49–55. [Google Scholar]
  8. Bosnjak, B.; Stelzmueller, B.; Erb, K.J.; Epstein, M.M. Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir. Res. 2011, 12, 114. [Google Scholar] [CrossRef] [Green Version]
  9. Alrumaihi, F.; Almatroudi, A.; Allemailem, K.S.; Rahmani, A.H.; Khan, A.; Khan, M.A. Therapeutic effect of bilsaan, Sambucus nigra stem exudate, on the OVA-induced allergic asthma in mice. Oxid. Med. Cell. Longev. 2020, 2020, 3620192. [Google Scholar] [CrossRef]
  10. Lambrecht, B.N.; Hammad, H.; Fahy, J.V. The cytokines of asthma. Immunity 2019, 50, 975–991. [Google Scholar] [CrossRef]
  11. Walsh, G.M. Anti-IL-4/-13 based therapy in asthma. Expert Opin. Emerg. Drugs 2015, 20, 349–352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Chu, X.; Ci, X.; He, J.; Wei, M.; Yang, X.; Cao, Q.; Li, H.; Guan, S.; Deng, Y.; Pang, D.; et al. A novel anti-inflammatory role for ginkgolide B in asthma via inhibition of the ERK/MAPK signaling pathway. Molecules 2011, 16, 7634–7648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Zhou, E.; Fu, Y.; Wei, Z.; Yu, Y.; Zhang, X.; Yang, Z. Thymol attenuates allergic airway inflammation in ovalbumin (OVA)-induced mouse asthma. Fitoterapia 2014, 96, 131–137. [Google Scholar] [CrossRef] [PubMed]
  14. Zhang, Q.; Wang, L.; Chen, B.; Zhuo, Q.; Bao, C.; Lin, L. Propofol inhibits NF-κB activation to ameliorate airway inflammation in ovalbumin (OVA)-induced allergic asthma mice. Int. Immunopharmacol. 2017, 51, 158–164. [Google Scholar] [CrossRef] [PubMed]
  15. Wang, C.; Choi, Y.H.; Xian, Z.; Zheng, M.; Piao, H.; Yan, G. Aloperine suppresses allergic airway inflammation through NF-κB, MAPK, and Nrf2/HO-1 signaling pathways in mice. Int. Immunopharmacol. 2018, 65, 571–579. [Google Scholar] [CrossRef] [PubMed]
  16. Su, Y.W.; Chiou, W.F.; Chao, S.H.; Lee, M.H.; Chen, C.C.; Tsai, Y.C. Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-κB and AP-1 signaling pathways. Int. Immunopharmacol. 2011, 11, 1166–1172. [Google Scholar] [CrossRef]
  17. Gu, X.; Zhang, Q.; Du, Q.; Shen, H.; Zhu, Z. Pinocembrin attenuates allergic airway inflammation via inhibition of NF-κB pathway in mice. Int. Immunopharmacol. 2017, 53, 90–95. [Google Scholar] [CrossRef]
  18. Santana, F.P.R.; da Silva, R.C.; Ponci, V.; Pinheiro, A.; Olivo, C.R.; Caperuto, L.C.; Arantes-Costa, F.M.; Claudio, S.R.; Ribeiro, D.A.; Tibério, I.; et al. Dehydrodieugenol improved lung inflammation in an asthma model by inhibiting the STAT3/SOCS3 and MAPK pathways. Biochem. Pharmacol. 2020, 180, 114175. [Google Scholar] [CrossRef]
  19. Liu, L.; Shang, Y.; Li, M.; Han, X.; Wang, J.; Wang, J. Curcumin ameliorates asthmatic airway inflammation by activating nuclear factor-E2-related factor 2/haem oxygenase (HO)-1 signalling pathway. Clin. Exp. Pharmacol. Physiol. 2015, 42, 520–529. [Google Scholar] [CrossRef]
  20. Liu, L.; Wang, L.P.; He, S.; Ma, Y. Immune homeostasis: Effects of Chinese herbal formulae and herb-derived compounds on allergic asthma in different experimental models. Chin. J. Integr. Med. 2018, 24, 390–398. [Google Scholar] [CrossRef]
  21. Jeong, J.H.; Moon, S.J.; Jhun, J.Y.; Yang, E.J.; Cho, M.L.; Min, J.K. Eupatilin exerts antinociceptive and chondroprotective properties in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. PLoS ONE 2015, 10, e0130882. [Google Scholar] [CrossRef] [PubMed]
  22. Nageen, B.; Sarfraz, I.; Rasul, A.; Hussain, G.; Rukhsar, F.; Irshad, S.; Riaz, A.; Selamoglu, Z.; Ali, M. Eupatilin: A natural pharmacologically active flavone compound with its wide range applications. J. Asian Nat. Prod. Res. 2020, 22, 1–16. [Google Scholar] [CrossRef] [PubMed]
  23. Choi, E.J.; Lee, S.; Chae, J.R.; Lee, H.S.; Jun, C.D.; Kim, S.H. Eupatilin inhibits lipopolysaccharide-induced expression of inflammatory mediators in macrophages. Life Sci. 2011, 88, 1121–1126. [Google Scholar] [CrossRef] [PubMed]
  24. Jeon, J.I.; Ko, S.H.; Kim, Y.J.; Choi, S.M.; Kang, K.K.; Kim, H.; Yoon, H.J.; Kim, J.M. The flavone eupatilin inhibits eotaxin expression in an NF-κB-dependent and STAT6-independent manner. Scand. J. Immunol. 2015, 81, 166–176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Song, E.H.; Chung, K.S.; Kang, Y.M.; Lee, J.H.; Lee, M.; An, H.J. Eupatilin suppresses the allergic inflammatory response in vitro and in vivo. Phytomedicine 2018, 42, 1–8. [Google Scholar] [CrossRef]
  26. Kim, J.Y.; Kwon, E.Y.; Lee, Y.S.; Kim, W.B.; Ro, J.Y. Eupatilin blocks mediator release via tyrosine kinase inhibition in activated guinea pig lung mast cells. J. Toxicol. Environ. Health Part A 2005, 68, 2063–2080. [Google Scholar]
  27. Liu, H.; Hao, J.; Wu, C.; Liu, G.; Wang, X.; Yu, J.; Liu, Y.; Zhao, H. Eupatilin alleviates lipopolysaccharide-induced acute lung injury by inhibiting inflammation and oxidative stress. Med. Sci. Monit. 2019, 25, 8289–8296. [Google Scholar] [CrossRef]
  28. He, J.; Lv, L.; Wang, Z.; Huo, C.; Zheng, Z.; Yin, B.; Jiang, P.; Yang, Y.; Li, J.; Gao, Y.; et al. Pulvis Fellis Suis extract attenuates ovalbumin-induced airway inflammation in murine model of asthma. J. Ethnopharmacol. 2017, 207, 34–41. [Google Scholar] [CrossRef]
  29. Liu, J.; Xiong, H.; Cheng, Y.; Cui, C.; Zhang, X.; Xu, L.; Zhang, X. Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. J. Ethnopharmacol. 2013, 148, 787–793. [Google Scholar] [CrossRef]
  30. Lee, I.T.; Yang, C.M. Inflammatory signalings involved in airway and pulmonary diseases. Mediat. Inflamm. 2013, 2013, 791231. [Google Scholar] [CrossRef] [Green Version]
  31. Yang, M.; Kumar, R.K.; Hansbro, P.M.; Foster, P.S. Emerging roles of pulmonary macrophages in driving the development of severe asthma. J. Leukoc. Biol. 2012, 91, 557–569. [Google Scholar] [CrossRef] [PubMed]
  32. Jiao, J.; Wu, J.; Wang, J.; Guo, Y.; Gao, L.; Liang, H.; Huang, J.; Wang, J. Ma Huang Tang ameliorates bronchial asthma symptoms through the TLR9 pathway. Pharm. Biol. 2018, 56, 580–593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Ma, S.Q.; Wei, H.L.; Zhang, X. TLR2 regulates allergic airway inflammation through NF-κB and MAPK signaling pathways in asthmatic mice. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 3138–3146. [Google Scholar] [PubMed]
  34. Abdelaziz, R.R.; Elmahdy, M.K.; Suddek, G.M. Flavocoxid attenuates airway inflammation in ovalbumin-induced mouse asthma model. Chem. Biol. Interact. 2018, 292, 15–23. [Google Scholar] [CrossRef] [PubMed]
  35. Ma, Y.; Ge, A.; Zhu, W.; Liu, Y.N.; Ji, N.F.; Zha, W.J.; Zhang, J.X.; Zeng, X.N.; Huang, M. Morin attenuates ovalbumin-induced airway inflammation by modulating oxidative stress-responsive MAPK signaling. Oxid. Med. Cell. Longev. 2016, 2016, 5843672. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Ci, X.; Chu, X.; Wei, M.; Yang, X.; Cai, Q.; Deng, X. Different effects of farrerol on an OVA-induced allergic asthma and LPS-induced acute lung injury. PLoS ONE 2012, 7, e34634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Tian, C.; Gao, F.; Li, X.; Li, Z. Icariside II attenuates eosinophils-induced airway inflammation and remodeling via inactivation of NF-κB and STAT3 in an asthma mouse model. Exp. Mol. Pathol. 2020, 113, 104373. [Google Scholar] [CrossRef]
  38. Cho, J.Y. Recent advances in mechanisms and treatments of airway remodeling in asthma: A message from the bench side to the clinic. Korean J. Intern. Med. 2011, 26, 367–383. [Google Scholar] [CrossRef]
  39. Gauvreau, G.M.; El-Gammal, A.I.; O’Byrne, P.M. Allergen-induced airway responses. Eur. Respir. J. 2015, 46, 819–831. [Google Scholar] [CrossRef] [Green Version]
  40. Zhi, Y.; Huang, H.; Liang, L. MFG-E8/integrin β3 signaling contributes to airway inflammation response and airway remodeling in an ovalbumin-induced murine model of asthma. J. Cell. Biochem. 2018, 119, 8887–8896. [Google Scholar] [CrossRef]
  41. Wu, D.; Li, S.; Liu, X.; Xu, J.; Jiang, A.; Zhang, Y.; Liu, Z.; Wang, J.; Zhou, E.; Wei, Z.; et al. Alpinetin prevents inflammatory responses in OVA-induced allergic asthma through modulating PI3K/AKT/NF-κB and HO-1 signaling pathways in mice. Int. Immunopharmacol. 2020, 89, 107073. [Google Scholar] [CrossRef] [PubMed]
  42. Wegmann, M. Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Rev. Mol. Diagn. 2009, 9, 85–100. [Google Scholar] [CrossRef] [PubMed]
  43. Shin, I.S.; Jeon, W.Y.; Shin, H.K.; Lee, M.Y. Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma. Int. Immunopharmacol. 2013, 17, 867–873. [Google Scholar] [CrossRef] [PubMed]
  44. Umetsu, D.T.; DeKruyff, R.H. TH1 and TH2 CD4+ cells in human allergic diseases. J. Allergy Clin. Immunol. 1997, 100, 1–6. [Google Scholar] [CrossRef]
  45. Mishra, V.; Banga, J.; Silveyra, P. Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets. Pharmacol. Ther. 2018, 181, 169–182. [Google Scholar] [CrossRef]
  46. Kunnumakkara, A.B.; Shabnam, B.; Girisa, S.; Harsha, C.; Banik, K.; Devi, T.B.; Choudhury, R.; Sahu, H.; Parama, D.; Sailo, B.L.; et al. Inflammation, NF-κB, and chronic diseases: How are they linked? Crit. Rev. Immunol. 2020, 40, 1–39. [Google Scholar] [CrossRef]
  47. Roy, S.; Manna, K.; Jha, T.; Saha, K.D. Chrysin-loaded PLGA attenuates OVA-induced allergic asthma by modulating TLR/NF-κB/NLRP3 axis. Nanomed. Nanotechnol. Biol. Med. 2020, 30, 102292. [Google Scholar] [CrossRef]
  48. Dai, R.; Niu, M.; Wang, N.; Wang, Y. Syringin alleviates ovalbumin-induced lung inflammation in BALB/c mice asthma model via NF-κB signaling pathway. Environ. Toxicol. 2021, 36, 433–444. [Google Scholar] [CrossRef]
  49. Yoon, W.J.; Moon, J.Y.; Song, G.; Lee, Y.K.; Han, M.S.; Lee, J.S.; Ihm, B.S.; Lee, W.J.; Lee, N.H.; Hyun, C.G. Artemisia fukudo essential oil attenuates LPS-induced inflammation by suppressing NF-κB and MAPK activation in RAW 264.7 macrophages. Food Chem. Toxicol. 2010, 48, 1222–1229. [Google Scholar] [CrossRef]
  50. Das, J.; Chen, C.H.; Yang, L.; Cohn, L.; Ray, P.; Ray, A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2001, 2, 45–50. [Google Scholar] [CrossRef]
  51. Abohassan, M.; Al Shahrani, M.; Alshahrani, M.Y.; Begum, N.; Radhakrishnan, S.; Rajagopalan, P. FNF-12, a novel benzylidene-chromanone derivative, attenuates inflammatory response in in vitro and in vivo asthma models mediated by M2-related Th2 cytokines via MAPK and NF-kB signaling. Pharmacol. Rep. 2022, 74, 96–110. [Google Scholar] [CrossRef] [PubMed]
  52. Son, E.S.; Park, J.W.; Kim, S.H.; Park, H.R.; Han, W.; Kwon, O.C.; Nam, J.Y.; Jeong, S.H.; Lee, C.S. Anti-inflammatory activity of 3,5,6,7,3′,4′-hexamethoxyflavone via repression of the NF-κB and MAPK signaling pathways in LPS-stimulated RAW264.7 cells. Mol. Med. Rep. 2020, 22, 1985–1993. [Google Scholar] [CrossRef] [PubMed]
  53. Kim, H.I.; Hong, S.H.; Ku, J.M.; Kang, S.; Kim, T.Y.; Shin, Y.C.; Ko, S.G. Tonggyu-tang, a traditional Korean medicine, suppresses pro-inflammatory cytokine production through inhibition of MAPK and NF-κB activation in human mast cells and keratinocytes. BMC Complement. Altern. Med. 2017, 17, 186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Ryter, S.W.; Choi, A.M. Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl. Res. J. Lab. Clin. Med. 2016, 167, 7–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Peters, M.C.; McGrath, K.W.; Hawkins, G.A.; Hastie, A.T.; Levy, B.D.; Israel, E.; Phillips, B.R.; Mauger, D.T.; Comhair, S.A.; Erzurum, S.C.; et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: A cross-sectional analysis of two cohorts. Lancet Respir. Med. 2016, 4, 574–584. [Google Scholar] [CrossRef] [Green Version]
  56. Luu Quoc, Q.; Cao Thi Bich, T.; Kim, S.H.; Park, H.S.; Shin, Y.S. Administration of vitamin E attenuates airway inflammation through restoration of Nrf2 in a mouse model of asthma. J. Cell. Mol. Med. 2021, 25, 6721–6732. [Google Scholar] [CrossRef]
  57. Fricker, M.; Gibson, P.G. Macrophage dysfunction in the pathogenesis and treatment of asthma. Eur. Respir. J. 2017, 50, 1700196. [Google Scholar] [CrossRef]
  58. Han, Y.; Yuan, C.; Zhou, X.; Han, Y.; He, Y.; Ouyang, J.; Zhou, W.; Wang, Z.; Wang, H.; Li, G. Anti-inflammatory activity of three triterpene from Hippophae rhamnoides L. in lipopolysaccharide-stimulated RAW264.7 cells. Int. J. Mol. Sci. 2021, 22, 12009. [Google Scholar] [CrossRef]
  59. Ou, G.; Liu, Q.; Yu, C.; Chen, X.; Zhang, W.; Chen, Y.; Wang, T.; Luo, Y.; Jiang, G.; Zhu, M.; et al. The protective effects of maresin 1 in the OVA-induced asthma mouse model. Mediat. Inflamm. 2021, 2021, 4131420. [Google Scholar] [CrossRef]
  60. Li, Q.; Bai, D.; Qin, L.; Shao, M.; Liu, X.; Zhang, S.; Yan, C.; Yu, G.; Hao, J. Protective effect of L-hexaguluroic acid hexasodium salt on UVA-induced photo-aging in HaCaT cells. Int. J. Mol. Sci. 2020, 21, 1201. [Google Scholar] [CrossRef] [Green Version]
  61. Xin, W.; Huang, C.; Zhang, X.; Zhang, G.; Ma, X.; Sun, L.; Wang, C.; Zhang, D.; Zhang, T.; Du, G. Evaluation of the new anti-inflammatory compound ethyl salicylate 2-O-β-d-glucoside and its possible mechanism of action. Int. Immunopharmacol. 2013, 15, 303–308. [Google Scholar] [CrossRef] [PubMed]
  62. Zou, J.; Zhang, Y.; Sun, J.; Wang, X.; Tu, H.; Geng, S.; Liu, R.; Chen, Y.; Bi, Z. Deoxyelephantopin induces reactive oxygen species-mediated apoptosis and autophagy in human osteosarcoma cells. Cell. Physiol. Biochem. 2017, 42, 1812–1821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 23 01582 g001 550
Figure 1. Chemical structure of eupatilin.
Figure 1. Chemical structure of eupatilin.
Ijms 23 01582 g001
Ijms 23 01582 g002 550
Figure 2. Effect of eupatilin on OVA-induced inflammatory cell count in the BALF. Twenty-four hours after the last challenge, the total inflammatory cells, neutrophils, lymphocytes, monocytes, and eosinophils in the BALF were counted. Data represent the mean ± SEM (n = 7). * p < 0.05, # p < 0.0001 vs. OVA group.
Figure 2. Effect of eupatilin on OVA-induced inflammatory cell count in the BALF. Twenty-four hours after the last challenge, the total inflammatory cells, neutrophils, lymphocytes, monocytes, and eosinophils in the BALF were counted. Data represent the mean ± SEM (n = 7). * p < 0.05, # p < 0.0001 vs. OVA group.
Ijms 23 01582 g002
Ijms 23 01582 g003 550
Figure 3. Effect of eupatilin on OVA-induced Th2 cytokines in the BALF and OVA-IgE levels in the serum were detected by ELISA. (a) BALF IL-5 levels. (b) BALF IL-13 levels. (c) Serum OVA-IgE levels. Data represent the mean ± SEM (n = 7). ## p < 0.001, #### p < 0.0001 vs. control group; * p < 0.05, *** p < 0.001, **** p < 0.0001 vs. OVA group.
Figure 3. Effect of eupatilin on OVA-induced Th2 cytokines in the BALF and OVA-IgE levels in the serum were detected by ELISA. (a) BALF IL-5 levels. (b) BALF IL-13 levels. (c) Serum OVA-IgE levels. Data represent the mean ± SEM (n = 7). ## p < 0.001, #### p < 0.0001 vs. control group; * p < 0.05, *** p < 0.001, **** p < 0.0001 vs. OVA group.
Ijms 23 01582 g003
Ijms 23 01582 g004 550
Figure 4. Effect of eupatilin on lung histological changes in OVA-induced asthmatic mice. (a) H&E staining was used to detect inflammatory cell infiltration. (b) PAS staining was used to detect the production of mucus around the airways. 200× magnification; scale bar: 50 μm.
Figure 4. Effect of eupatilin on lung histological changes in OVA-induced asthmatic mice. (a) H&E staining was used to detect inflammatory cell infiltration. (b) PAS staining was used to detect the production of mucus around the airways. 200× magnification; scale bar: 50 μm.
Ijms 23 01582 g004
Ijms 23 01582 g005 550
Figure 5. Effect of eupatilin on NF-κB, MAPK, and Nrf2 signaling pathways in OVA-induced asthmatic mice. (a) Western blotting analyses of NF-κB p65, p-NF-κB p65, p38 MAPK, p-p38 MAPK, Erk, p-Erk, JNK, p-JNK, and Nrf2 protein expression in lung tissues. (b) Quantification of the p-NF-κB p65/NF-κB p65 ratio. (c) Quantification of the p-p38 MAPK/p38 MAPK ratio. (d) Quantification of the p-Erk/Erk ratio. (e) Quantification of the p-JNK/JNK ratio. (f) Quantification of the Nrf2/GAPDH ratio. Data represent the mean ± SEM (n = 3). ### p < 0.001, #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. OVA group.
Figure 5. Effect of eupatilin on NF-κB, MAPK, and Nrf2 signaling pathways in OVA-induced asthmatic mice. (a) Western blotting analyses of NF-κB p65, p-NF-κB p65, p38 MAPK, p-p38 MAPK, Erk, p-Erk, JNK, p-JNK, and Nrf2 protein expression in lung tissues. (b) Quantification of the p-NF-κB p65/NF-κB p65 ratio. (c) Quantification of the p-p38 MAPK/p38 MAPK ratio. (d) Quantification of the p-Erk/Erk ratio. (e) Quantification of the p-JNK/JNK ratio. (f) Quantification of the Nrf2/GAPDH ratio. Data represent the mean ± SEM (n = 3). ### p < 0.001, #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. OVA group.
Ijms 23 01582 g005
Ijms 23 01582 g006 550
Figure 6. Effect of eupatilin on inflammatory cytokines in LPS-stimulated RAW264.7 cells. RAW264.7 cells were induced with 1 µg/mL LPS and treated with various concentrations (10, 25, 50, and 100 µmol/L) of eupatilin for 24 h. (a) Cell viability after treatment with different concentrations of eupatilin for 24 h. (b) NO levels in cell supernatants after LPS and eupatilin treatment. (c) IL-6 levels in cell supernatants after LPS and eupatilin treatment. (d) ROS levels in RAW264.7 cells treated with LPS and eupatilin. 630× magnification; scale bar: 25 μm. Data represent the mean ± SEM (n = 4). #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, **** p < 0.0001 vs. LPS group.
Figure 6. Effect of eupatilin on inflammatory cytokines in LPS-stimulated RAW264.7 cells. RAW264.7 cells were induced with 1 µg/mL LPS and treated with various concentrations (10, 25, 50, and 100 µmol/L) of eupatilin for 24 h. (a) Cell viability after treatment with different concentrations of eupatilin for 24 h. (b) NO levels in cell supernatants after LPS and eupatilin treatment. (c) IL-6 levels in cell supernatants after LPS and eupatilin treatment. (d) ROS levels in RAW264.7 cells treated with LPS and eupatilin. 630× magnification; scale bar: 25 μm. Data represent the mean ± SEM (n = 4). #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, **** p < 0.0001 vs. LPS group.
Ijms 23 01582 g006
Ijms 23 01582 g007 550
Figure 7. Effect of eupatilin on NF-κB, MAPK, and Nrf2 signaling pathways in LPS-stimulated RAW264.7 cells. After RAW264.7 cells were treated with LPS and eupatilin for 24 h, intracellular proteins were extracted for subsequent Western blotting analysis. (a) Western blotting analyses of NF-κB p65, p-NF-κB p65, p38 MAPK, p-p38 MAPK, Erk, p-Erk, JNK, p-JNK, and Nrf2 protein expression in LPS-stimulated RAW264.7 cells. (b) Quantification of the p-NF-κB p65/NF-κB p65 ratio. (c) Quantification of the p-p38 MAPK/p38 MAPK ratio. (d) Quantification of the p-Erk/Erk ratio. (e) Quantification of the p-JNK/JNK ratio. (f) Quantification of the Nrf2/GAPDH ratio. Data represent the mean ± SEM (n = 3). ## p < 0.01, #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. LPS group.
Figure 7. Effect of eupatilin on NF-κB, MAPK, and Nrf2 signaling pathways in LPS-stimulated RAW264.7 cells. After RAW264.7 cells were treated with LPS and eupatilin for 24 h, intracellular proteins were extracted for subsequent Western blotting analysis. (a) Western blotting analyses of NF-κB p65, p-NF-κB p65, p38 MAPK, p-p38 MAPK, Erk, p-Erk, JNK, p-JNK, and Nrf2 protein expression in LPS-stimulated RAW264.7 cells. (b) Quantification of the p-NF-κB p65/NF-κB p65 ratio. (c) Quantification of the p-p38 MAPK/p38 MAPK ratio. (d) Quantification of the p-Erk/Erk ratio. (e) Quantification of the p-JNK/JNK ratio. (f) Quantification of the Nrf2/GAPDH ratio. Data represent the mean ± SEM (n = 3). ## p < 0.01, #### p < 0.0001 vs. control group; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. LPS group.
Ijms 23 01582 g007
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Bai, D.; Sun, T.; Lu, F.; Shen, Y.; Zhang, Y.; Zhang, B.; Yu, G.; Li, H.; Hao, J. Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice. Int. J. Mol. Sci. 2022, 23, 1582. https://doi.org/10.3390/ijms23031582

AMA Style

Bai D, Sun T, Lu F, Shen Y, Zhang Y, Zhang B, Yu G, Li H, Hao J. Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice. International Journal of Molecular Sciences. 2022; 23(3):1582. https://doi.org/10.3390/ijms23031582

Chicago/Turabian Style

Bai, Donghui, Tianxiao Sun, Fang Lu, Yancheng Shen, Yan Zhang, Bo Zhang, Guangli Yu, Haihua Li, and Jiejie Hao. 2022. "Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice" International Journal of Molecular Sciences 23, no. 3: 1582. https://doi.org/10.3390/ijms23031582

APA Style

Bai, D., Sun, T., Lu, F., Shen, Y., Zhang, Y., Zhang, B., Yu, G., Li, H., & Hao, J. (2022). Eupatilin Suppresses OVA-Induced Asthma by Inhibiting NF-κB and MAPK and Activating Nrf2 Signaling Pathways in Mice. International Journal of Molecular Sciences, 23(3), 1582. https://doi.org/10.3390/ijms23031582

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop